JFOUND: O’Connor, Owen [MC1982] Co-Founder Therasis, Inc.

2015-Feb-21

http://www.bloomberg.com/research/stocks/private/person.asp?personId=32677349&privcapId=82661644&previousCapId=82661644&previousTitle=Therasis,%20Inc.

Owen A. O’Connor M.D., Ph.D.
Co-Founder and Director, Therasis, Inc.

Dr. Owen A. O’Connor, M.D., Ph.D. serves taken in the character of Attending Physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City, to what Dr. O’Connor serves as the Head of the Laboratory of Experimental Therapeutics concerning the Lymphoproliferative Malignancies. He serves to the degree that an associate professor of medicine and a guide of the Lymphoid Development and Malignancy program at Columbia University Medical Center.

Dr. O’Connor co-founded Therasis, Inc. in 2007.

His examination interests focus on the discovery and disclosure of novel small molecules for the management of hematologic malignancies. Dr. O’Connor is an internationally recognized leader in the finding and development of new drugs in favor of the treatment of hematologic malignancies, in nice lymphoma.

To date his laboratory and clinical careful search efforts have led to the U.S. FDA approval of manifold drugs for the treatment of lymphoma, including the proteasome inhibitor bortezomib with respect to the treatment of mantle cell lymphoma, the histone deacetylase inhibitor vorinostat on this account that the treatment of cutaneous T-cell lymphoma (CTCL), and most recently pralatrexate, the pristine drug ever approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

Dr. O’Connor co-invented and developed pralatrexate at Memorial Sloan-Kettering Cancer Center, which became the first drug ever approved through the FDA for the treatment of patients by relapsed or refractory peripheral T-confined apartment lymphoma.

He serves as Member of Scientific Advisory Board at Stemline Therapeutics, Inc.

He served considered in the state of Member of Medical Advisory Board of Cornerstone Pharmaceuticals, Inc.

Dr. O’Connor went in successi~ to do a medical internship and residency at the New York Hospital-Cornell University Medical Center. Following his therapeutic residency, he did a fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center, and a Fellowship in Clinical Pharmacology at the New York Hospital-Cornell University Medical School. Dr. O’Connor current his B.S. in Biology, magna cum laude, from Manhattan College in 1982, his Ph.D. in Biochemical Toxicology and Chemical Carcinogenesis from NYU School of Medicine, and his M.D. from the University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School in 1994.

# – # – # – # – #  

O’Connor, Owen [MC1982]

# – # – # – # – #  2015-Feb-21 @ 12:30  

About these ads

Lexapro does not become greater agitation, anxiety or nervousness within the calm when compared to his condition before outset of Lexapro treatment.

Recent Comments

    Archives